Allogene Therapeutics

Allogene is advancing ALLO-329 – an investigational “off-the-shelf” AlloCAR T™ product for autoimmune disease, powered by our proprietary Dagger® technology. See how we’re aiming to reset the immune system, expand access and transform care. #autoimmune #CART #celltherapy #allogeneic Uncover the Potential of ALLO-329: Allogene.com/Pipeline

Our own Zach Roberts had an inspiring conversation with media powerhouse Katie Couric about the evolution of #CART and how the ALPHA3 trial could change the game. Thanks so much for having us Katie Couric Media. We had a blast!

Allogene’s ALPHA3 trial, studying an investigational allogeneic #CART therapy as a potential option to help prevent relapse in #LBCL patients, has been highlighted in USA TODAY. Proud to be working toward the future of cancer care. Learn More About ALPHA3: https://lnkd.in/g8SWf_px

A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #LBCL #CART #celltherapy #allogeneic Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar

A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #LBCL #CART #celltherapy #allogeneic Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar

We're proud to have Katie Couric highlight our work. Allogene's ALPHA3 trial is studying an investigational allogeneic #CART as a potential option to help prevent relapse in #LBCL patients at highest risk. Learn how this innovation could shape the future of cancer care. Katie Couric Media Learn More: https://lnkd.in/gg8x5yhR

Looking forward to this discussion between Foresight Diagnostics' Chief Business Officer John Truesdell and our own Zachary J Roberts at #FierceBiotechWeek! Learn how next-generation #MRD is reshaping oncology and informing clinical decision making to improve patient outcomes. Register Here: https://bit.ly/4nk0C1A

Today, our EVP, R&D and CMO Zachary J Roberts will participate in the Citi SMID Biotech call series; tune in to learn more about our lead trials and where we see allogeneic CAR T fitting into the broader cell therapy landscape. A recording will be available in the investors section of our website. View the Webcast Here: https://lnkd.in/eBV4zW9

1 in 3 LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an “off-the-shelf” CAR T product to intervene early and potentially improve cure rates. #LBCL #CART #celltherapy #allogeneic Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar

Looking forward to discussing how next-generation MRD may transform oncology. #FierceBiotechWeek